Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Down State Medical F18 FDG review cancelled

Executive Summary

A Nov. 19 review of Down State Medical's positron emission tomography agent F18 fluoro-D-glucose (FDG) for the diagnosis and/or identification of Alzheimer's disease progression has been cancelled. FDA's Peripheral & Central Nervous System Drugs Committee still will discuss the use of Alzheimer's brain imaging as a surrogate endpoint in clinical trials on Nov. 18 (1"The Pink Sheet" Sept. 30, In Brief)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS040763

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel